Accutane 20mg

Dragon Pharma Accutane — Pharmaceutical-Grade Isotretinoin 20mg

Dragon Pharma Accutane delivers 20 mg of Isotretinoin per tablet. This retinoid compound is widely regarded as the most effective systemic therapy for severe, treatment-resistant acne vulgaris.

For athletes experiencing androgen-induced sebaceous hyperactivity, this agent targets the underlying pathophysiology. It dramatically reduces sebum output, normalizes follicular keratinization, and suppresses cutaneous inflammation.

Overview

Isotretinoin is a synthetic derivative of vitamin A belonging to the retinoid class. It modulates epidermal cell proliferation, differentiation, and apoptosis through nuclear receptor-mediated gene expression.

The compound addresses all four pillars of acne pathogenesis. It shrinks sebaceous glands, prevents microcomedone formation, reduces Cutibacterium acnes colonization, and exerts direct anti-inflammatory activity.

Unlike topical or antibiotic therapies that require indefinite maintenance, a single structured course frequently produces durable remission. Clinical literature indicates approximately 85% of patients achieve long-term clearance after one protocol.

Dragon Pharma manufactures each tablet with pharmaceutical precision. Independent laboratory analysis confirmed 20.93 mg of active Isotretinoin per unit. This accuracy supports precise cumulative dosing calculations and predictable therapeutic outcomes.

Benefits

• Profound Sebum Suppression: Reduces sebaceous gland activity by up to 90% within the first 4–8 weeks. This eliminates the lipid-rich environment that fuels acne pathogenesis.
• Follicular Normalization: Regulates desquamation within the pilosebaceous unit, preventing keratinocyte accumulation and subsequent pore obstruction.
• Antibacterial Environment: By depleting sebum availability, the compound indirectly suppresses Cutibacterium acnes proliferation and biofilm formation.
• Anti-Inflammatory Action: Directly attenuates cytokine-mediated inflammation, calming existing papules, pustules, and nodulocystic lesions.
• Durable Remission: A complete 15–20 week course frequently delivers permanent or near-permanent clearance, unlike therapies that relapse upon discontinuation.
• Scar Prevention: By halting severe lesion formation, Isotretinoin reduces the risk of atrophic and hypertrophic scarring while improving overall dermal texture.

Main Features

• Precisely dosed 20 mg oral tablets for weight-based titration
• Synthetic retinoid with multi-modal anti-acne pharmacology
• Systemic action targeting all four pathogenic factors of acne
• High lipophilicity requiring administration with dietary fats
• Independent laboratory verification of active concentration
• Supports long-term remission after a single treatment course

Ingredients

Each tablet contains 20 mg of Isotretinoin as the active pharmaceutical ingredient.

Inactive excipients include microcrystalline cellulose, pregelatinized starch, magnesium stearate, and film-coating agents. These ensure tablet stability, dissolution consistency, and protection from oxidative degradation.

All raw materials undergo identity and purity validation prior to formulation and compression.

How to Use

Ingest tablets with a meal containing at least 15–20 grams of dietary fat. Lipid co-administration increases bioavailability by approximately 60% compared to fasted administration.

Divide the daily total into two administrations—morning and evening—to maintain stable plasma concentrations and reduce gastrointestinal irritation.

Store the container in a cool, dry environment between 15–25°C (59–77°F). Protect from light and moisture. Keep the desiccant pouch intact.

Dosage

Standard therapy is calculated at 0.5–1.0 mg per kilogram of body weight daily. A 91 kg individual would target 45–90 mg per day, divided into two doses.

Low-dose protocols utilize 10–20 mg daily. This approach reduces mucocutaneous side effects while still delivering significant therapeutic benefit, particularly for maintenance or moderate presentations.

The cumulative treatment target is 120–150 mg per kilogram of total body weight. For a 91 kg individual, this equals 10,920–13,650 mg over the entire course.

A standard protocol lasts 15–20 weeks. After completion, a break period allows for assessment of remission status before considering any additional course.

Side Effects

Mucocutaneous dryness is nearly universal. Users experience chapped lips, xerosis, dry nasal mucosa, and ocular irritation. These are expected pharmacological effects reflecting sebaceous suppression.

Hepatic enzyme elevations may occur. Regular liver function panels every 4–6 weeks are mandatory throughout the treatment period.

Lipid abnormalities are common. Triglyceride and cholesterol elevations affect approximately 25% of patients. Dietary modification and lipid monitoring are essential.

Musculoskeletal complaints including myalgia, arthralgia, and back discomfort may emerge. Athletes engaged in intense resistance training should monitor for tendon and joint symptoms.

Psychiatric effects including mood alterations and depressive symptoms have been reported. While causality remains debated, users and supervisors should remain vigilant for behavioral changes.

Visual disturbances such as impaired night vision and dry eye syndrome may affect contact lens tolerance. Ophthalmologic evaluation is warranted if symptoms persist.

Safety Information

This product is intended exclusively for research purposes and use by qualified adults under appropriate medical supervision. It is absolutely contraindicated in pregnancy.

Isotretinoin is a potent teratogen. Women of childbearing potential must use two forms of effective contraception for one month before, during, and for one month following therapy.

Avoid all hepatotoxic substances including alcohol and oral anabolic steroids during treatment. Concurrent hepatotoxicity significantly amplifies hepatic risk.

Regular monitoring of liver enzymes, fasting lipids, and complete blood counts is mandatory. Discontinue immediately and seek medical evaluation if jaundice, severe abdominal pain, or visual disturbances develop.

Do not donate blood during therapy and for one month after cessation. Transfusion recipients could receive the teratogenic agent.

Maintain adequate hydration and joint support supplementation during the active phase. Topical emollients and lip balms mitigate mucocutaneous dryness.